Patents Assigned to Oncodesign S.A.
  • Patent number: 10676486
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 9, 2020
    Assignee: ONCODESIGN S.A.
    Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
  • Patent number: 10377772
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 13, 2019
    Assignee: Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Publication number: 20190127390
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Application
    Filed: September 17, 2015
    Publication date: May 2, 2019
    Applicant: ONCODESIGN S.A.
    Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
  • Publication number: 20170240565
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 24, 2017
    Applicants: Oncodesign S.A., Ipsen Pharma S.A.S.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Patent number: 9586975
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 7, 2017
    Assignee: ONCODESIGN S.A.
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack, Pascal Andre Rene Benderitter
  • Patent number: 9370519
    Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: June 21, 2016
    Assignee: Oncodesign S.A.
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack
  • Publication number: 20160024113
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: ONCODESIGN S.A.
    Inventors: Petra Marcella, Francoise BLOM, Jan Marie, Cyriel, Jozef HOFLACK, Pascal Andre, Rene BENDERITTER
  • Publication number: 20160024114
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: ONCODESIGN S.A.
    Inventors: Petra Marcella, Francoise Blom, Jan Marie Cyriel Jozef Hoflack, Pascal Andre, Rene Benderitter
  • Patent number: 9096609
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 4, 2015
    Assignees: Ipsen Pharma S.A.S., Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom
  • Patent number: 9090630
    Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 28, 2015
    Assignee: Oncodesign S.A.
    Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack